This report studies the Breast Cancer Monoclonal Antibodies market size by players, regions, product types and end industries, history data 2013-2017 and forecast data 2018-2025; This report also studies the global market competition landscape, market drivers and trends, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter’s Five Forces Analysis.
Click to view the full report TOC, figure and tables：https://www.qyresearch.com
Email us with your all Requirements,
Request A Sample and Brochure or Request For Custom Research (price, discount, regional reports, and chapters only, analyst talk and etc.)
Please Email US:
Benefits of Purchasing QYResearch Research Report
- Analyst SupportGet you queries resolved from our expert analysts before and after purchasing the report
- Customer’s SatisfactionOur expert team will assist with all your research needs and customize the report
- Inimitable ExpertiseAnalysts will provide deep insights about the reports
- Assured QualityWe focus on the quality and accuracy of the report
Breast cancer is characterized by the malignancy of cells in the tissues of the breast. HER-2 breast cancer is the most common type of breast cancer. The HER-2 protein, present on the surface of normal breast cells, affects the growth of the malignant cells. The uncontrolled synthesis of this protein stimulates the growth and division of malignant cells.
The breast cancer monoclonal antibodies (mAbs) market is one of the fastest-growing segments of the global mAbs market and has gained major research significance among biotech and pharmaceutical companies due to the presence of high unmet needs in this area. Antibodies are increasingly becoming the best choice to treat cancers, including breast cancer. The use of antibody-drug conjugates (ADCs),including radioimmunotherapy and antibody-directed enzyme prodrug therapy, is increasing rapidly. ADCs are highly effective cytotoxic drugs linked to mAbs. These drugs have shown to be potent and efficient in treating breast cancer. This has propelled vendors to focus on novel technologies such as Seattle Genetics (SGEN), ImmunoGen (IMGN), and Immunomedics (IMMU). The rising use of these antibodies in drug development increases revenue generation in the breast cancer mAbs market, contributing to market growth.
The breast cancer mAbs market in APAC will witness a high growth rate during the forecast period due to the better market penetration of breast cancer mAbs and biosimilars in emerging economies, especially in Japan, Australia, India, South Korea, and China. The rising number of initiatives undertaken by major vendors to assist patients in these countries is a significant contributor to the rise in sales of breast cancer mAbs in these countries. Moreover, the growing awareness about breast cancer and the available treatment alternatives will also propel growth prospects for the market growth in APAC.
In 2017, the global Breast Cancer Monoclonal Antibodies market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% between 2018 and 2025.
This report focuses on the global top players, covered
Sun Pharmaceutical Industries
Market segment by Regions/Countries, this report covers
Rest of Asia Pacific
Central & South America
Middle East & Africa
Market segment by Type, the product can be split into
Market segment by Application, the market can be split into
The study objectives of this report are:
To study and forecast the market size of Breast Cancer Monoclonal Antibodies in global market.
To analyze the global key players, SWOT analysis, value and global market share for top players.
To define, describe and forecast the market by type, end use and region.
To analyze and compare the market status and forecast among global major regions.
To analyze the global key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends and factors driving or inhibiting the market growth.
To analyze the opportunities in the market for stakeholders by identifying the high growth segments.
To strategically analyze each submarket with respect to individual growth trend and their contribution to the market
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
In this study, the years considered to estimate the market size of Breast Cancer Monoclonal Antibodies are as follows:
History Year: 2013-2017
Base Year: 2017
Estimated Year: 2018
Forecast Year 2018 to 2025
For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Raw material suppliers
Regulatory bodies, including government agencies and NGO
Commercial research & development (R&D) institutions
Importers and exporters
Government organizations, research organizations, and consulting firms
Trade associations and industry bodies
With the given market data, QYResearch offers customizations according to the company’s specific needs. The following customization options are available for the report:
Further breakdown of Breast Cancer Monoclonal Antibodies market on basis of the key contributing countries.
Detailed analysis and profiling of additional market players.